Literature DB >> 11508439

Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma).

D D Wallis1, F K Tan, C M Kielty, M D Kimball, F C Arnett, D M Milewicz.   

Abstract

OBJECTIVE: To determine if there are abnormalities in fibrillin 1-containing microfibrils in the extracellular matrix (ECM) of primary dermal fibroblasts explanted from patients with systemic sclerosis (SSc).
METHODS: Explanted fibroblasts from unaffected skin of 12 SSc patients were used to examine fibrillin 1-containing microfibrils by immunofluorescence (IF) using a monoclonal antibody (mAb) to fibrillin 1. Metabolic labeling of the fibroblast cultures was used to study the synthesis, secretion, and processing of fibrillin 1, as well as to observe microfibril formation and stability. Microfibrils elaborated by the SSc cells were analyzed by electron microscopy for ultrastructural abnormalities, and the results were confirmed by immunoblotting.
RESULTS: Control and SSc fibroblasts displayed a prominent meshwork of fibrillin 1-containing microfibrils when visualized by IF using a fibrillin 1 mAb. Paradoxically, metabolic studies indicated a paucity of fibrillin 1 in the ECM in the majority of the SSc fibroblast strains. Subsequent rotary-shadowed electron microscopy revealed reduced amounts of and ultrastructural abnormalities in the microfibrils elaborated by all strains of SSc cells. Immunoblots confirmed the lack of the high molecular weight form of fibrillin 1 in the SSc fibroblasts of Choctaw American Indians. Finally, in vitro studies indicated that the amount of fibrillin 1 in the ECM of SSc cells diminished at a faster rate than the amount of fibrillin 1 in the ECM of control cells with time.
CONCLUSION: Although SSc fibroblasts assemble microfibrils, these microfibrils are unstable, suggesting that an inherent defect of fibrillin 1-containing microfibrils may play a role in the pathogenesis of SSc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508439     DOI: 10.1002/1529-0131(200108)44:8<1855::AID-ART324>3.0.CO;2-Q

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

Review 1.  The genetics of systemic sclerosis.

Authors:  Randall W Johnson; Monty B Tew; Frank C Arnett
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

2.  Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients.

Authors:  Loubna Chadli; Britt Sotthewes; Kejie Li; Stefan N Andersen; Ellen Cahir-McFarland; Marc Cheung; Patrick Cullen; Annemarie Dorjée; Jeska K de Vries-Bouwstra; Tom W J Huizinga; David F Fischer; Jeroen DeGroot; Joanne L Viney; Timothy S Zheng; Jamil Aarbiou; Agnes Gardet
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

3.  The Immunogenetics of Systemic Sclerosis.

Authors:  Begüm Ünlü; Ümit Türsen; Zeynab Rajabi; Navid Jabalameli; Fateme Rajabi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Fibrillin-1 in incisional hernias: an immunohistochemical study in scar and non-scar regions of human skin and muscle fasciae.

Authors:  Martin Fricke; Claus Langer; Edgar Brunner; Lynn Y Sakai; Laszlo Füzesi; Dieter P Reinhardt; Fabio Quondamatteo
Journal:  J Anat       Date:  2008-04-10       Impact factor: 2.610

Review 5.  Antibodies in scleroderma: direct pathogenicity and phenotypic associations.

Authors:  Lorinda Chung; Paul J Utz
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 6.  Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations.

Authors:  John D Reveille
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

7.  Absence of autoantibodies against correctly folded recombinant fibrillin-1 protein in systemic sclerosis patients.

Authors:  Jürgen Brinckmann; Nico Hunzelmann; Ehab El-Hallous; Thomas Krieg; Lynn Y Sakai; Sven Krengel; Dieter P Reinhardt
Journal:  Arthritis Res Ther       Date:  2005-09-06       Impact factor: 5.156

Review 8.  Animal models of systemic sclerosis: their utility and limitations.

Authors:  Carol M Artlett
Journal:  Open Access Rheumatol       Date:  2014-07-01

9.  Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide.

Authors:  Marilisa Villano; Annalisa Borghini; Mirko Manetti; Erica Gabbrielli; Antonella Rossi; Piersante Sestini; Anna Milia; Francesca Nacci; Serena Guiducci; Marco Matucci-Cerinic; Lidia Ibba-Manneschi; Elisabetta Weber
Journal:  Arthritis Res Ther       Date:  2013-08-20       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.